Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.98 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.98 |
| ▸ | HTT | P42858 | 2/20 | 0.98 |
| ▸ | THRB | P10828 | 2/20 | 0.98 |
| ▸ | TDP2 | O95551 | 1/20 | 0.98 |
| ▸ | FGB | P02675 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.98 |
| ▸ | RECQL | P46063 | 1/20 | 0.98 |
| ▸ | RAB9A | P51151 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinocide SCHEMBL29720457 | 1.00 | MEN1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Quinocide SCHEMBL28060369 | 0.99 | HSP90AA1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Quinocide SCHEMBL30823571 | 0.99 | HSP90AA1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Quinocide SCHEMBL707955 | 0.99 | HSP90AA1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Quinocide SCHEMBL2286358 | 0.94 | MEN1 (0.88) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL17792862 | 0.85 | HSP90AA1 (0.93) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL8893299 | 0.84 | HSP90AA1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Pentaquine SCHEMBL980723 | 0.84 | HSP90AA1 (0.74) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Pentaquine SCHEMBL29596989 | 0.84 | HSP90AA1 (0.74) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL8900580 | 0.83 | HSP90AA1 (0.98) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105481766-B | A kind of preparation method of quinocide and its hydrochloride | 河南省科学院高新技术研究中心 | 2017-11-17 | — | — | CN | claimed |
| CN-105481766-A | Quinocide and preparation method of hydrochloride thereof | HIGH & NEW TECH RES CENTER OF HENAN ACAD OF SCIENCES | 2016-04-13 | — | — | CN | claimed |
| US-8889153-B2 | Combination of immunomodulator and anti-pathogenic agent | NUNES ISEU DA SILVA (BR) | 2014-11-18 | — | — | US | claimed |
| EP-2259799-B1 | COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT | NUNES ISEU DA SILVA (BR) | 2014-03-12 | — | — | EP | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2013018069-A1 | COMBINATION OF ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-07 | — | — | WO | claimed |
| US-20120121724-A1 | FILM COMPRISING THERAPEUTIC AGENTS | MAIBACH TODD (US) | 2012-05-17 | — | — | US | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| US-20110028385-A1 | Combination of Immunomodulator and Anti-Pathogenic Agent | NUNES ISEU DA SILVA | 2011-02-03 | — | — | US | claimed |
| WO-2005004989-A2 | FILM COMPRISING THERAPEUTIC AGENTS | MAIBACH TODD (US) | 2005-01-20 | — | — | WO | claimed |
| EP-1135481-A1 | NEW OLIGOMERIC CONJUGATES LIABLE TO TRANSFER BIOLOGICAL MOLECULES INTO CELLS | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 2001-09-26 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000032764-A1 | NEW OLIGOMERIC CONJUGATES LIABLE TO TRANSFER BIOLOGICAL MOLECULES INTO CELLS | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 2000-06-08 | — | — | WO | claimed |
| WO-1996009049-A1 | INHIBITION OF PLASMODIA PARASITES BY CAMPTOTHECIN COMPOUNDS | RESEARCH TRIANGLE INSTITUTE (US) | 1996-03-28 | — | — | WO | claimed |
| EP-0422097-B1 | METHOD OF INHIBITING THE ACTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN VIVO | DAVIS MICHAEL H (US) | 1994-04-27 | — | — | EP | claimed |
| EP-0422097-A4 | METHOD OF INHIBITING THE ACTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN VIVO | — | 1992-03-11 | — | — | EP | claimed |
| EP-0422097-A1 | METHOD OF INHIBITING THE ACTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN VIVO. | DAVIS MICHAEL H (US) | 1991-04-17 | — | — | EP | claimed |
| WO-1990000055-A1 | METHOD OF INHIBITING THE ACTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN VIVO | DAVIS MICHAEL H (US) | 1990-01-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | MEN1 2829/4885KMT2A 3867/4885HSP90AA1 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.